Arcadia Capital has successfully advised InformedDNA on the divestiture of its genetic testing utilization management business unit to Zyter. This strategic move marks a significant transition for both organizations as they realign their core operations within the healthcare technology sector.
InformedDNA focuses on providing expert clinical genetic insights. By offloading its utilization management division, the company streamlines its internal focus toward its primary genetic counseling and health system integration services. This decision allows management to concentrate resources on its core genetic health expertise.
Zyter acquires this business unit to expand its service offerings. The integration of genetic testing management into the Zyter platform aims to broaden the scope of its clinical support tools. Both parties have finalized the terms of the transaction to ensure a transition for existing clients and partners.
This divestiture reflects the current shift in healthcare companies looking to sharpen their focus on specific market niches rather than maintaining broad service portfolios. Arcadia Capital managed the advisory process, ensuring that the deal aligns with the long-term goals of the involved parties. Further details on the operational impact are expected to emerge as the transition completes over the coming months.